Related Experiment Video
Updated: Jul 10, 2026
07:33
Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
Published on: September 19, 2025
[Carcinoembryonal antigen (CEA) in malignant lymphomas].
Srpski Arhiv Za Celokupno Lekarstvo
|May 1, 1994
Summary
Elevated Carcinoembryonic antigen (CEA) levels are not typically found in patients with Hodgkin or non-Hodgkin lymphomas. Sporadic elevations below 10 ng/ml were observed, but significant increases warrant further diagnostic investigation.
Area of Science:
- Oncology
- Clinical Chemistry
Context:
- Carcinoembryonic antigen (CEA) is a tumor marker, literature suggests it can be elevated in various cancers, including those of mesodermal origin.
- Malignant lymphomas are cancers of the lymphatic system, originating from lymphocytes (a type of white blood cell).
Purpose:
- To investigate the association between elevated Carcinoembryonic antigen (CEA) serum levels and the presence of malignant lymphomas (Hodgkin and non-Hodgkin).
- To determine the circumstances under which CEA levels might be elevated in lymphoma patients.
Summary:
- This study found no significant association between Hodgkin or non-Hodgkin lymphomas and elevated Carcinoembryonic antigen (CEA) serum levels.
- Observed sporadic CEA elevations in lymphoma patients did not exceed 10 ng/ml.
- Significant elevations in CEA necessitate further diagnostic workup beyond lymphoma diagnosis.
Impact:
- Clarifies the limited utility of CEA as a biomarker for diagnosing or monitoring malignant lymphomas.
- Highlights the importance of targeted diagnostic strategies for lymphoma patients presenting with elevated CEA.
- Contributes to a better understanding of tumor marker specificity in hematological malignancies.